Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence